8-K: MetaVia Inc. Announces Exercise of Pre-Funded Warrants and Provides Corporate Update

MetaVia Inc. reports the exercise of pre-funded warrants and provides an update on its corporate presentation and clinical programs targeting obesity and MASH.

Summary

• MetaVia Inc. announced the exercise of pre-funded common stock purchase warrants to purchase 1,430,000 shares of common stock.
• Following the exercise, the company has 10,084,869 shares of common stock issued and outstanding as of April 15, 2025.
• The company posted an updated corporate presentation to its website on April 15, 2025, which it may use in connection with presentations, investor communications, or conferences.
• The corporate presentation includes forward-looking statements and information about the company's pipeline of therapeutics targeting obesity and MASH.
• Key programs include DA-1726, a GLP1R/GCGR dual agonist for obesity, and DA-1241, a GPR119 agonist for MASH.
• Phase 1 MAD topline results for DA-1726 were released in April 2025, showing strong weight loss and glucose-lowering effects.
• Phase 2a topline data for DA-1241 in subjects with presumed MASH met the primary endpoint and showed direct hepatic effects.
• The company is actively seeking a combination/licensing partner for DA-1241.
• As of December 31, 2024, MetaVia had $16.0 million in cash and no debt.
• The company aims to increase shareholder value through multiple, near-term, value-creating milestones.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting promising clinical data and strategic milestones. However, it also acknowledges risks related to funding and regulatory approvals, tempering the overall sentiment.

Positives

• DA-1726 shows strong weight loss and glucose-lowering potential in Phase 1 trials.
• DA-1726 demonstrates a favorable safety profile with no treatment-related discontinuations.
• DA-1241 Phase 2a data indicates direct hepatic effects, suggesting potential for MASH treatment.
• The company has a clear strategy to increase shareholder value through near-term milestones.
• The company has $16 million in cash with no debt.

Negatives

• The company has incurred net losses since inception and anticipates continuing to do so.
• The company requires additional capital to execute its business plan.
• The company does not generate any revenue and is dependent on working capital to fund its business plan.
• The company's future success depends on regulatory and clinical success, which is not guaranteed.

Risks

• The company's ability to execute its commercial strategy is subject to risks.
• The sufficiency of the company's existing cash on hand to fund its operations is a risk.
• The timeline for regulatory submissions and potential approval of product candidates is uncertain.
• The company's ability to realize the benefits of the license agreement with Dong-A ST Co., Ltd. is a risk.
• The company's ability to integrate product candidates into its business in a timely and cost-efficient manner is a risk.
• The cooperation of contract manufacturers and clinical study partners is crucial and poses a risk.
• The company's ability to initiate clinical trials on a timely basis and recruit subjects is a risk.
• Changes in applicable laws or regulations could adversely affect the company.
• Changes to the company's stock price could affect the terms of the license agreement and future fundraising.

Future Outlook

The company is focused on advancing its clinical programs for DA-1726 and DA-1241, exploring partnerships, and achieving key milestones to increase shareholder value. The company plans to explore maximum tolerated dose of DA-1726 in additional cohorts.

Industry Context

The document highlights MetaVia's focus on the growing markets for obesity and MASH treatments, aligning with industry trends and recent transactions involving GLP-1 agonists and other metabolic disease therapies. The document references recent transactions such as Novo Nordisk / United Biotechnology, AbbVie / Gubra, Roche / Zealand Pharma, Carmot Therapeutics / Roche, Versanis Bio / Eli Lilly, and Inversago Pharma / Novo Nordisk.

Comparison to Industry Standards

• DA-1726's weight loss results are being compared to Survodutide in pre-clinical models, suggesting a focus on competitive efficacy.
• The company is positioning DA-1726 as potentially best-in-class for GLP-1R/GCGR dual agonists, indicating an awareness of competitors like Boehringer Ingelheim and Zealand Pharma.
• The document references Semaglutide as a comparator in NASH models, indicating an awareness of existing treatments.
• The company is actively seeking a combination/licensing partner for DA-1241, similar to Roche's collaboration with Zealand Pharma on Petrelintide.

Stakeholder Impact

• Shareholders may be impacted by the exercise of warrants and the company's progress in clinical development.
• Employees are impacted by the company's ability to secure funding and advance its programs.
• Patients with obesity and MASH may benefit from the development of new therapies.
• The company's suppliers and partners are impacted by its financial stability and clinical progress.

Next Steps

• The company plans to continue clinical development of DA-1726, including exploring maximum tolerated dose and evaluating its effects in Wegovy early drop-out patients.
• The company will release other exploratory endpoints including MRI-PDFF at major medical conferences for DA-1241.
• The company will actively search for a combination/licensing partner for DA-1241.
• The company plans to meet with the FDA in H1 2025.
• The company plans to submit Phase 1 Part 3 IND Amend in Q2 2025.
• The company plans to have Phase 1 Part 3 First Patient In in Q3 2025.
• The company plans to have Phase 1 Part 3 Interim Data Readout in H1 2026.

Key Dates

Keywords

MetaVia, Obesity, MASH, DA-1726, DA-1241, GLP1R/GCGR dual agonist, GPR119 agonist, Clinical trials, Pharmaceuticals, Biotech